OXURION (EBR:OXUR) | Finanzwire

Basculer en Français

11118	Companies
244805	Keywords
172884	Articles
131993	Press releases

Home
Companies
OXURION

PRESS RELEASE

published on 10/03/2025 at 18:00, 1 year ago

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
Atlas Special Opportunities, LLC converts 4 convertible bonds in Oxurion, leading to EUR 100,000 capital increase. Oxurion issues 5,990,086 new ordinary shares as part of EUR 20m Capital Commitment with Atlas. Company's total outstanding shares now 56,367,609

Shares Convertible Bonds Capital Increase Atlas Special Opportunities Oxurion
BRIEF

published on 10/02/2025 at 18:05, 1 year ago

Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC

Actions Transparency Pharmaceutical Atlas Special Opportunities Oxurion
PRESS RELEASE

published on 10/02/2025 at 18:00, 1 year ago

Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC
Oxurion NV received a transparency notification from Atlas Special Opportunities II, LLC regarding changes in shareholding. The company specializes in acquiring stakes in European pharmaceutical subcontractors. Risks associated with forward-looking statements and planned investments in digital assets are highlighted

Forward-looking Statements Digital Assets Transparency Notification Oxurion NV Pharmaceutical Subcontractors
BRIEF

published on 09/30/2025 at 18:05, 1 year ago

Oxurion 2025 Half-Year Results: Financial and Operational Analysis

Financial Results Digital Assets Forecasts Oxurion Pharmaceutical Subcontractors
PRESS RELEASE

published on 09/30/2025 at 18:00, 1 year ago

Oxurion Publishes First Half 2025 Results
Oxurion NV releases financial and business update for the six-month period ending June 30, 2025. The half-year report is available on the company's website. Oxurion specializes in acquiring pharmaceutical subcontractors

Acquisition Business Update Pharmaceutical Financial Update Oxurion NV
BRIEF

published on 09/16/2025 at 18:05, 1 year ago

Oxurion and Axiodis CRO leverage AI to revolutionize clinical trials

Artificial Intelligence Clinical Trials Oxurion Digital Twins Axiodis CRO
PRESS RELEASE

published on 09/16/2025 at 18:00, 1 year ago

Axiodis CRO, the French subsidiary of the Oxurion Group, announces a dual AI-driven strategic initiative to transform clinical trials
Axiodis CRO, a subsidiary of Oxurion NV, leverages AI to enhance clinical trials with digital twins for disease simulation and AI modules integrated into Exagis eCRF solution for improved data quality and workflow efficiency

AI Integration Clinical Trials Oxurion NV Digital Twins Axiodis CRO
BRIEF

published on 09/08/2025 at 18:05, 1 year ago

Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC

Actions Transparency Atlas Special Opportunities Financial Risks Oxurion
PRESS RELEASE

published on 09/08/2025 at 18:00, 1 year ago

Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC
Oxurion NV receives transparency notification from Atlas Special Opportunities II, LLC regarding change in shareholding. Oxurion specializes in acquiring majority stakes in European pharmaceutical subcontractors

Transparency Notification Shareholding Change Oxurion NV Belgian Transparency Legislation European Pharmaceutical Subcontractors
BRIEF

published on 09/01/2025 at 18:05, 1 year 1 month ago

Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC

Actions Transparency Atlas Special Opportunities Oxurion Participation Thresholds

Accesswire

Published on 10/03/2026 at 02:35, 1 day 1 hour ago

Jaguar Health Announces a Special Stock Dividend
Published on 10/02/2026 at 17:45, 1 day 10 hours ago

Sparton Provides Status Update
Published on 10/02/2026 at 13:50, 1 day 14 hours ago

AI/ML Innovations Appoints Lynn Chapman as Chief Financial Officer and Announces Share Issuance for Debt Settlement
Published on 10/02/2026 at 13:00, 1 day 15 hours ago

Evergold Drills 4.9 m of 7.70 g/t Au and 186.0 g/t Ag Within 13.5 Metres of 2.84 g/t Au and 127.6 g/t Ag in First 2026 Drill Holes at Golden Lion
Published on 10/02/2026 at 13:00, 1 day 15 hours ago

Alaska Energy Metals Appoints Independent Director, Thomas Benson

View all ACCESSWIRE

EQS Group

Published on 10/03/2026 at 15:45, 12 hours 38 minutes ago

Huawei Highlights Continuous Innovation, Securing Competitive Edge Through Technological Breakthroughs
Published on 10/02/2026 at 23:55, 1 day 4 hours ago

IS SKINCARE GETTING TOO COMPLICATED? CERAVE MAKES THE CASE FOR SAFETY, EFFICACY AND SIMPLICITY
Published on 10/02/2026 at 20:23, 1 day 8 hours ago

EQS-Adhoc: Pentixapharm Holding AG: Bafin concludes financial reporting review of the 2024 consolidated financial statements with an error finding
Published on 10/02/2026 at 19:46, 1 day 8 hours ago

innoscripta SE: Update on the Tax Authorities’ Investigation – Business Operations Continue as Usual – Full Transparency Assured – Invitation to Shareholders for an In-Person Product Presentation
Published on 10/02/2026 at 18:00, 1 day 10 hours ago

EQS-Adhoc: AMUNDI PHYSICAL GOLD ETC (the “ETC”): Release of the first Supplemental Base Prospectus (the “Supplemental”)

Les Echos

Published on 10/02/2026 at 17:45, 1 day 10 hours ago

Information concerning the total number of voting rights and shares 2026 09 30
Published on 10/02/2026 at 17:30, 1 day 10 hours ago

Aéroports de Paris SA - 2027 Financial Calendar
Published on 10/01/2026 at 19:00, 2 days 9 hours ago

AMA CORP PLC reduces its cost base while preserving XpertEye’s key functions
Published on 10/01/2026 at 18:40, 2 days 9 hours ago

Monthly disclosure of the total number of shares and voting rights - September 2026
Published on 10/01/2026 at 18:05, 2 days 10 hours ago

Covivio - Information on total number of voting rights and share capital

View all LES ECHOS COMFI WIRE